43 completed, 8 recruiting, 6 terminated, 3 active not recruiting. 67 Phase 3, 10 Phase 2.
Follow Proteinuria: new trials by email Literature Review of Proteinuria trials Research Report on Proteinuria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-11-03 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i ARBs alone, ARBs in combination of SGLT2i - Proteinuria, Diabetes (DM) | Phase 2 / Phase 3 | Active not recruiting | Dr Mudassar Saeed Pansota | 60 | 2026-04-06 | 2026-05-14 |
| FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors Finerenone (BAY 94-8862), Placebo - Chronic Kidney Disease | Phase 3 | Enrolling by invitation | University Medical Center Groningen | 180 | 2026-03-13 | 2026-04-14 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN iptacopan - Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 31 | 2025-11-27 | 2026-09-09 |
| SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome Dapagliflozin, Empagliflozin, Standard Therapy - Nephrotic Syndrome | Phase 2 / Phase 3 | Recruiting | Mansoura University | 75 | 2025-11-15 | 2026-06-09 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| The Efficacy and Safety of Dapagliflozin in the Treatment of Hereditary Kidney Disease With Proteinuria in Children Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks, Standard Treatment alone for 12 weeks ,washout period for 4 weeks ,then Dapagliflozin+Standard Treatment for 12 weeks - Pediatric Hereditary Kidney Diseases | Phase 3 | Recruiting | Children's Hospital of Fudan University | 44 | 2025-03-22 | 2026-07-06 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Placebo, iptacopan - IC-MPGN | Phase 3 | Recruiting | Novartis Pharmaceuticals | 106 | 2023-10-02 | 2026-07-13 |
| A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Finerenone (Kerendia, BAY94-8862) - Chronic Kidney Disease, Proteinuria | Phase 3 | Recruiting | Bayer | 100 | 2022-11-08 | 2026-09-24 |
| A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria Finerenone (Kerendia, BAY94-8862), Placebo - Chronic Kidney Disease, Proteinuria | Phase 3 | Active not recruiting | Bayer | 219 | 2022-03-28 | 2026-10-15 |
| SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes Semaglutide, Placebo - Obesity, Albuminuria | Phase 3 | Completed | University Medical Center Groningen | 125 | 2022-03-14 | 2025-04-22 |
| SER150 vs Placebo in Diabetic Kidney Disease SER150, Placebo - Diabetic Kidney Disease | Phase 2 / Phase 3 | Completed | Serodus AS | 20 | 2021-08-18 | 2024-06-21 |
| Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Placebo, iptacopan - C3G | Phase 3 | Recruiting | Novartis Pharmaceuticals | 98 | 2021-07-28 | 2026-11-05 |
| Steroids Therapy in IgA Nephropathy With Crescents Methylprednisolone - IgA Nephropathy | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 200 | 2021-05-24 | 2021-06-04 |
| Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Placebo, LNP023 - IgA Nephropathy | Phase 3 | Completed | Novartis Pharmaceuticals | 517 | 2021-01-25 | 2026-11-04 |
| Empagliflozin in Patients With Glomerulonephritis Empagliflozin 25 MG, placebo - Glomerulonephritis, Proteinuria | Phase 3 | Completed | Kasr El Aini Hospital | 50 | 2020-02-20 | 2022-03-16 |
| Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients pegunigalsidase alfa - Fabry Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 29 | 2018-11-13 | 2026-05-22 |
Showing 20 of 67. Sign in to see all of them.
Albuminuria (16) · Renal Insufficiency, Chronic (14) · Glomerulonephritis, IGA (13) · Diabetic Nephropathies (12) · Kidney Diseases (9) · Diabetes Mellitus, Type 2 (8) · Diabetes Mellitus (7) · Glomerulonephritis (6) · Hypertension (6) · Fabry Disease (3) · Nephritis (3) · Hemoglobinuria (2) · Hemoglobinuria, Paroxysmal (2) · Inflammation (2)
Female Urogenital Diseases (67) · Female Urogenital Diseases and Pregnancy Complications (67) · Male Urogenital Diseases (67) · Pathological Conditions, Signs and Symptoms (67) · Signs and Symptoms (67) · Urination Disorders (67) · Urological Manifestations (67) · Urogenital Diseases (66) · Urologic Diseases (65) · Kidney Diseases (33) · Pathologic Processes (20) · Disease Attributes (17) · Nutritional and Metabolic Diseases (17) · Chronic Disease (16) · Endocrine System Diseases (16)
Losartan (5) · iptacopan (4) · finerenone (3) · Acetylcysteine (2) · Fatty Acids, Omega-3 (2) · Methylprednisolone (2) · Mycophenolic Acid (2) · Olmesartan Medoxomil (2) · Pentoxifylline (2) · Prednisone (2) · Rituximab (2) · Standard of Care (2) · dapagliflozin (2) · empagliflozin (2) · glucuronyl glucosamine glycan sulfate (2)
Novartis Pharmaceuticals (5) · Bayer (3) · Alexion Pharmaceuticals, Inc. (2) · AstraZeneca (2) · Chiesi Farmaceutici S.p.A. (2) · Daiichi Sankyo Co., Ltd. (2) · Keryx Biopharmaceuticals (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Seoul National University Hospital (2) · Shiraz University of Medical Sciences (2) · University Medical Center Groningen (2) · A. Manzoni Hospital (1) · AO GENERIUM (1) · Albert Einstein College of Medicine (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (23) · Canada (14) · Spain (14) · Italy (13) · Australia (12) · Germany (12) · Netherlands (12) · Czechia (11) · South Korea (11) · United Kingdom (10) · France (9) · Japan (9) · Taiwan (9) · Argentina (8) · China (8)
Hee Gyung Kang, Ph.D (2) · Alessia Fornoni, M.D. (1) · Amin Banihashemi (1) · Anne Reutens, MD (1) · Branimir Draganov, MD (1) · Dong-Ryeol Ryu, Professor (1) · Edmund J Lewis, M.D. (1) · Ellen Burgess, MD (1)
PMID 38299639, PMID 38682786, PMID 35675911, PMID 37772889, PMID 37916745, PMID 38864363, PMID 10093981, PMID 10676716, PMID 11532109, PMID 11877568, PMID 14694168, PMID 18700466, PMID 19211712, PMID 19216016, PMID 20541301, PMID 20671225, PMID 21285125, PMID 21872376, PMID 21993710, PMID 22386035, PMID 22739977, PMID 23207876, PMID 23675422, PMID 23782179, PMID 24013685, PMID 25592855, PMID 26630142, PMID 27291448, PMID 27539604, PMID 27878313, PMID 28290633, PMID 28341274, PMID 28763548, PMID 28893924, PMID 29141939, PMID 29168475, PMID 29253846, PMID 29441742, PMID 29589183, PMID 29937267, PMID 30062716, PMID 30134956, PMID 30412655, PMID 30619615, PMID 30992195, PMID 32030417, PMID 32149007, PMID 32803882, PMID 32855502, PMID 33107592
2023 (2), 1KL2RR025015-01 (1), 2016 (1), 2025 (1), K23DK078774 (1), P20GM109036 (1), P30DK017047 (1), R01DK090316 (1)